Glenmark Pharmaceuticals (NSE:GLENMARK) EV-to-FCF: (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLENMARK Glenmark Pharmaceuticals Ltd NSE:GLENMARK
88 GF Score
Price ₹2,199.90
GF Value ₹1,985.29
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Glenmark Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Glenmark Pharmaceuticals's Enterprise Value is ₹612,256 Mil. Glenmark Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, Glenmark Pharmaceuticals's EV-to-FCF for today is .

The historical rank and industry rank for Glenmark Pharmaceuticals's EV-to-FCF or its related term are showing as below:

NSE:GLENMARK' s EV-to-FCF Range Over the Past 10 Years
Min: 0   Med: 0   Max: 29.84
Current: 29.84

During the past 13 years, the highest EV-to-FCF of Glenmark Pharmaceuticals was 29.84. The lowest was 0.00. And the median was 0.00.

NSE:GLENMARK's EV-to-FCF is ranked worse than
59.58% of 569 companies
in the Drug Manufacturers industry
Industry Median: 21.07 vs NSE:GLENMARK: 29.84

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-23), Glenmark Pharmaceuticals's stock price is ₹2199.90. Glenmark Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹48.240. Therefore, Glenmark Pharmaceuticals's PE Ratio (TTM) for today is 45.60.


Glenmark Pharmaceuticals  (NSE:GLENMARK) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Glenmark Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2199.90/48.240
=45.60

Glenmark Pharmaceuticals's share price for today is ₹2199.90.
Glenmark Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹48.240.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Glenmark Pharmaceuticals EV-to-FCF Related Terms


Glenmark Pharmaceuticals EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Glenmark Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glenmark Pharmaceuticals EV-to-FCF Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.18 959.82 -22.84 -28.03 28.45

Glenmark Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.03 0.00 0.00 0.00 28.45

NSE:GLENMARK vs ZTS, UTHR: EV-to-FCF Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glenmark Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's EV-to-FCF falls into.


NSE:GLENMARK
88GF Score
Glenmark Pharmaceuticals Ltd NSE:GLENMARK
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glenmark Pharmaceuticals EV-to-FCF Calculation

Glenmark Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=612256.098/0
=

Glenmark Pharmaceuticals's current Enterprise Value is ₹612,256 Mil.
Glenmark Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Overvalued in 2026?

Based on GuruFocus' analysis, Glenmark Pharmaceuticals stock appears to be overvalued. The current stock price of ₹2,199.90 is trading 10.8% above its estimated GF Value™ of ₹1,985.29. GuruFocus considers Glenmark Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for NSE:GLENMARK:

  • EV-to-FCF:
  • GF Value™: ₹1,985.29 vs. price of ₹2,199.90 (10.8% above fair value)
  • GF Score™: 88/100 with 2 warning signs

No single metric tells the full story. See the NSE:GLENMARK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Glenmark Pharmaceuticals Business Description

Other Exchanges 532296:India
Address B. D. Sawant Marg, Glenmark House, Chakala, Off Western Express Highway, Andheri (East), Mumbai, MH, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
88GF Score

Get the complete analysis for NSE:GLENMARK

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,199.90
Price
₹1,985.29
GF Value